Merck, Inc.
🇺🇸United States
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
Phase 1
Terminated
- Conditions
- Myelogenous LeukemiaLeukemia, Lymphoblastic, Acute, T-cellChronic Lymphocytic LeukemiaMyelodysplastic Syndromes
- First Posted Date
- 2004-12-24
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00100152
A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)
Phase 2
Completed
- Conditions
- Acquired Immunodeficiency SyndromeHIV Infections
- Interventions
- Drug: Placebo monotherapy
- First Posted Date
- 2004-12-23
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 206
- Registration Number
- NCT00100048
Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers
Phase 1
Completed
- Conditions
- Cardiovascular Disease
- First Posted Date
- 2004-12-15
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00099450
- Locations
- 🇺🇸
Quintiles Phase I Services, Lenexa, Kansas, United States
MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001)
Phase 1
Terminated
- Conditions
- Colorectal CancerAdvanced Solid Tumors
- First Posted Date
- 2004-12-13
- Last Posted Date
- 2015-06-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00099346
An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)
Phase 2
Completed
- Conditions
- B-cell Lymphoma
- First Posted Date
- 2004-12-02
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT00097929
Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)
Phase 2
Terminated
- Conditions
- AIDSHIV Infections
- Interventions
- Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)
- First Posted Date
- 2004-11-08
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3000
- Registration Number
- NCT00095576
An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Chronic Renal Insufficiency
- Interventions
- First Posted Date
- 2004-11-01
- Last Posted Date
- 2015-04-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 91
- Registration Number
- NCT00095056
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)
- First Posted Date
- 2004-10-25
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1172
- Registration Number
- NCT00094770
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2004-10-25
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 521
- Registration Number
- NCT00094757
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
Phase 2
Completed
- Conditions
- LeiomyosarcomaMetastasesLiposarcomaOsteosarcomaSarcoma, Soft Tissue
- Interventions
- First Posted Date
- 2004-10-04
- Last Posted Date
- 2015-02-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 216
- Registration Number
- NCT00093080
© Copyright 2025. All Rights Reserved by MedPath